Heyman S N, Heyman A, Halperin I
Hadassah University Hospital, Mt. Scopus, Jerusalem, Israel.
DICP. 1989 Mar;23(3):236-7. doi: 10.1177/106002808902300309.
This case report describes a 60-year-old diabetic patient whose daily insulin requirements increased by 30 percent following nifedipine administration. Glucagon and intravenous glucose tolerance tests were performed with and without nifedipine treatment, in order to evaluate the roles of decreased pancreatic beta islet cell function and augmented insulin peripheral resistance in the diabetogenic effect of nifedipine. Insulin and calculated glucose peripheral utilization extrapolated from the glucose concentration curves were not significantly different. C-peptide levels tended to be lower with nifedipine treatment at baseline and during the glucagon tests. This may suggest that the altered glycemic control associated with nifedipine was mediated by a suppressed islet beta cell function. The effect of calcium channel-blockers upon glycemic control and the possible mechanisms involved are discussed.
本病例报告描述了一名60岁的糖尿病患者,其硝苯地平给药后每日胰岛素需求量增加了30%。为了评估胰腺β胰岛细胞功能降低和胰岛素外周抵抗增加在硝苯地平致糖尿病作用中的作用,在有和没有硝苯地平治疗的情况下进行了胰高血糖素和静脉葡萄糖耐量试验。胰岛素和从葡萄糖浓度曲线推算出的计算葡萄糖外周利用率没有显著差异。在基线和胰高血糖素试验期间,硝苯地平治疗的C肽水平往往较低。这可能表明与硝苯地平相关的血糖控制改变是由胰岛β细胞功能受抑制介导的。讨论了钙通道阻滞剂对血糖控制的影响及其可能的作用机制。